Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Lung Diseases, Obstructive

Lung Diseases, Obstructive

Subtypes of Lung Diseases, Obstructive

Chronic Obstructive Pulmonary Disease 149 Asthma 118 Bronchiolitis 6 Bronchitis 3

256 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Lung Diseases, Obstructive

7 trials tracked for Lung Diseases, Obstructive: 4 in phase 3 or 4.

7Trials tracked
4Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 4 1 Phase 3 3 Phase 2 1 Other / NA 2
  1. Phase 4 Individualizing Treatment for Asthma in Primary Care Completed
  2. Phase 3 Airway Effects of Tiotropium in Patients With COPD Completed
  3. Phase 3 26 Week Efficacy, Safety and Tolerability Study of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Completed
  4. Phase 3 Study of Acid Reflux in Asthma Completed
  5. Phase 2 Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE) Completed
  6. N/A Feasibility of Performing Peripheral Pulmonary Lesion Biopsy Using Robotic Bronchoscopy-Guided Cryoprobe Completed
Show 1 more trials
  1. N/A Asthma Data Innovation Demonstration Project Completed

Showing the 7 most-cited and recently-updated of 7 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

Lung Diseases, Obstructive: current evidence & treatments

Structured physical activity and exercise interventions show significant benefits in obstructive lung diseases. In asthma, structured physical activity improves FEV1% predicted by 5.79 and quality of life (PAQLQ) 1. In idiopathic pulmonary fibrosis, structured exercise improves 6-minute walk distance by 38.62 m 2. For COPD, water-based Liuzijue exercise is most effective for improving FEV1%pred (MD 9.51) 23, and IoT-assisted pulmonary rehabilitation protocols are being investigated 5. COPD patients also exhibit heightened sympathetic nerve activity compared to healthy adults 9.

Pharmacological and management strategies vary. Anti-inflammatory reliever therapy (AIR) reduces severe exacerbations compared to SABA-only in asthma 14. Casirivimab plus imdevimab reduces hospitalization or death in COVID-19 patients with and without asthma 6. In IPF, pirfenidone reduces lung cancer incidence by 73% (RR 0.39) 17. For pulmonary embolism, ultrasound-facilitated catheter-directed alteplase reduces early recurrence 20. Telemedicine strategies, especially combined approaches, improve asthma control and quality of life 18. However, 14% of COPD patients decline or discontinue long-term PAP therapy 10.

Genetic and environmental factors contribute to disease risk. HLA-DPA1 and HLA-DPB1 are downregulated in pediatric asthma with high diagnostic value 11. FAM13A variants influence tissue destruction in COPD and fibrotic remodeling in pulmonary fibrosis 13. Maternal free vitamin D is linked to offspring asthma risk 7. Prenatal beta-2-agonist exposure is associated with increased ASD risk (aOR 1.34) 16. Ultra-processed food consumption is associated with asthma in children 3. PM2.5 exposure may increase asthma risk in susceptible individuals 22. The respiratory microbiome offers insights for precision treatment 21.

Latest findings

AI-generated synthesis of 18 cited studies, updated Jun 12, 2026. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Nurse-driven HFNC weaning protocol cuts therapy duration by 16 hours, hospital stay by 1 day in bronchiolitis infants
Pediatrics RCT
Nurse-driven HFNC weaning protocol cuts therapy duration by 16 hours, hospital stay by 1 day in bronchiolitis infants Can letting nurses decide when to reduce breathing support help babies with bronchiolitis get home faster?
In infants with severe bronchiolitis, a nurse-driven high-flow nasal cannula (HFNC) weaning protocol significantly reduced median HFNC durat…
A nurse-driven checklist helped babies with severe bronchiolitis get off breathing support 34 hours sooner, cut hospital stays, and kept the…
Mar 30, 2026
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma
Allergy & Immunology Phase II
Phase 2 Study Evaluates Brenipatide for Moderate-to-Severe Asthma Could a new drug help people with severe asthma breathe easier?
A Phase 2 trial is assessing the safety and efficacy of brenipatide versus placebo in 531 participants with moderate-to-severe asthma.
A new asthma drug trial aims to reduce flare-ups and improve breathing for adults with moderate-to-severe asthma over the next year.
CT.gov Mar 28, 2026
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma
Allergy & Immunology Phase II
Phase 2b Study Evaluates KT-621 for Eosinophilic Asthma Can KT-621 help people with severe asthma breathe easier?
A Phase 2b trial is assessing KT-621's efficacy and safety in 264 adults with moderate to severe eosinophilic asthma.
A new drug called KT-621 is being tested to help people with uncontrolled moderate to severe eosinophilic asthma breathe easier by improving…
CT.gov Mar 28, 2026
IMP2ART Pilot Shows Feasibility for Asthma Self-Management in UK Primary Care
Allergy & Immunology RCT
IMP2ART Pilot Shows Feasibility for Asthma Self-Management in UK Primary Care Could Better Asthma Management Save You from Unnecessary Doctor Visits?
The IMP2ART pilot cRCT demonstrated feasibility and acceptability of an asthma self-management strategy in UK primary care, with successful …
A new UK strategy helps asthma patients breathe easier and avoid emergency room visits through personalized action plans and regular profess…
Mar 27, 2026